Immunic, Inc. Key Metrics

2 years of history · ending 2014-12-31 · SEC EDGAR

Forensics

Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.

F-Score (Piotroski 0-9)

Working Capital Analysis

52-Week Range

ROIC vs WACC

Liquidity & Leverage Ratios

Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)

EPS (Diluted)
Book Value Per Share
Free Cash Flow Per Share
Cash Per Share
OCF Per Share
Return on Equity
-180.2%
Return on Assets
-61.6%
Return on Invested Capital
-150.3%
Current Ratio
10.20
Quick Ratio
10.20
Working Capital
$95M
Net Current Asset Value
$105M
Invested Capital
$98M
OCF / Net Income
0.86
FCF / Net Income
0.89
Accruals Ratio (Sloan)
-6.3%
Net Debt
$-102M
Net Debt / EBITDA
2.08
Interest Coverage
Cash Coverage
Capex Coverage
-28.97
Tangible Common Equity
$98M
TCE / Total Assets
90.3%
Goodwill / Total Assets
NOPAT
$-40M
Cash ROIC
-159.7%
Capex / D&A
1.30
Reinvestment Rate
-0.6%
Book Value 5Y CAGR
Stock Price (FY-end)
$10K
Market Cap
P/B Ratio
P/TB Ratio
Enterprise Value
FCF Yield
Shareholder Yield
R&D Yield
Capex Yield
Shares Variation (YoY)
Beta (5Y)
1.31
Cost of Equity
11.0%
52W High
$13K
52W Low
$5K
Trailing Return 1Y
Trailing Return 5Y
F-Score (Piotroski)
3.00

Earnings Forecasts

Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).

Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.

EPS — Consensus vs Actual

Stock Price on Earnings Dates

Immunic, Inc. — Effective Tax Rate ReconciliationNEW

Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.

Effective Rate Trend

Reconciliation LineFY2020FY2021FY2022FY2023FY2024FY2025
Federal Statutory Rate21.00%21.00%21.00%21.00%21.00%21.00%
State & Local Income Taxes0.00%0.00%
Foreign Rate Differential3.00%3.20%2.20%3.10%2.80%
Other Adjustments
R&D Tax Credits
SBC (Nondeductible)-0.90%-0.90%-1.10%-1.20%-1.40%
Valuation Allowance Change-20.30%-22.90%-15.70%-24.10%-17.60%
Tax Law Change-1.90%0.00%0.00%0.00%
Effective Tax Rate0.00%0.00%0.00%0.00%0.00%0.00%

Cash vs Accrual

ItemFY2020FY2021FY2022FY2023FY2024FY2025
Income Tax Expense (Accrual)
Income Taxes Paid (Cash)